Functional evaluation of multidrug resistance transporter activity in surgical samples of solid tumors

Assay and Drug Development Technologies

Volumn 5, Issue 4, 2007, Pages 541-550

  Schwab, Richard ^a   Micsik, Tamás ^a   Szokolóczi, Orsolya ^a   Schafer, Eszter ^b   Tihanyi, Balázs ^a   Tihanyi, Tibor ^a   Kupcsulik, Péter ^a   Diófalvi, Katalin ^b   Mersich, Tamás ^c   Besznyak Jr , Istvan ^c   Zarand, Attila ^c   Mihalik, Rudolf ^a,d   Sarkadi, Balázs ^e   Kéri, György ^a   Pap, Ákos ^b   Jakab, Ferenc ^c   Kopper, László ^a,d   Petak, Istvan ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b MAV Hospital   (Hungary)

^c UZSOKI HOSPITAL   (Hungary)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^e NATIONAL MEDICAL CENTER   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

7 AMINODACTINOMYCIN; BEREP4 ANTIGEN; CALCEIN; CELL ANTIGEN; COLLAGENASE; CYANINE DYE 5; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; UNCLASSIFIED DRUG;

ANTIGENICITY; ARTICLE; ASSAY; BIOACCUMULATION; CANCER PATIENT; CELL SUSPENSION; CELL VIABILITY; COLORECTAL CANCER; CONJUGATION; EPITHELIUM CELL; EVALUATION; FLOW CYTOMETRY; FORCEPS; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; HUMAN TISSUE; PHENOTYPE; SOLID TUMOR; STAINING; TUMOR BIOPSY; TUMOR CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; BIOLOGICAL MARKERS; BIOPSY; BODY FLUIDS; CARCINOMA; CELL SEPARATION; CELL SURVIVAL; FLUORESCEINS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; KERATINS; LEUKEMIA P388; NEOPLASMS; P-GLYCOPROTEIN;

EID: 35148858214     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2007.067     Document Type: Article

References (43)

1. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.
2. Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA: Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 1992;267:4854-4858.
3. Grant CE, Valdimarsson G, Hipfher DR, Almquist KC, Cole SP, Deeley RG: Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994;54:357-361.
4. Leonard GD, Fojo T, Bates SE: The role of ABC transporters in clinical practice. Oncologist 2003;8:411-424.
5. Bruggemann EP, Currier SJ, Gottesman MM, Pastan I: Characterization of the azidopine and vinblastine binding site of P-glycoprotein. J Biol Chem 1992;267:21020-21026.
6. Arceci RJ: Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993;81:2215-2222.
7. Davidson B, Dong HP, Berner A, Christensen J, Nielsen S, Johansen P, et al.: Detection of malignant epithelial cells in effusions using flow cytometric immunophenotyping: an analysis of 92 cases. Am J Clin Pathol 2002;118:85-92.
8. Herweijer H, van den Engh G, Nooter K: A rapid and sensitive flow cytometric method for the detection of multidrug-resistant cells. Cytometry 1989;10:463-468.
9. Wall DM, Hu XF, Zalcberg JR, Parkin JD: Rapid functional assay for multidrug resistance in human tumor cell lines using the fluorescent indicator fluo-3. J Natl Cancer Inst 1991;83:206-207.
10. Kramer R, Weber TK, Arceci R, Ramchurren N, Kastrinakis WV, Steele G, et al.: Inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype. Br J Cancer 1995;71:670-675.
11. Lee WP: P-glycoprotein is hyperphosphorylated in multidrug resistant HOB1 lymphoma cells treated with overdose of vincristine. Biochim Biophys Acta 1995;1245:57-61.
12. Zhang JT, Ling V: Study of membrane orientation and glycosylated extracellular loops of mouse P-glycoprotein by in vitro translation. J Biol Chem 1991;266:18224-18232.
13. Neyfakh AA: Use of fluorescent dyes as molecular probes for the study of multidrug resistance. Exp Cell Res 1988;174:168-176.
14. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985;260:3440-3450.
15. Handbook of Fluorescent Probes and Research Chemicals (Larison K, ed.), pp. 163, 172-173. Molecular Probes, Eugene, OR, 1992.
16. Kessel D, Beck WT, Kukuruga D, Schulz V: Characterization of multidrug resistance by fluorescent dyes. Cancer Res 1991;51:4665-4670.
17. Liminga G, Nygren P, Larsson R: Microfluorometric evaluation of calcein acetoxymethyl ester as a probe for P-glycoprotein-mediated resistance: effects of cyclosporin A and its nonimmunosuppressive analogue SDZ PSC 833. Exp Cell Res 1994;212:291-296.
18. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, et al.: The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 2000;113:2011-2021.
19. Homolya L, Holló Z, Germann UA, Pastan I, Gottesman MM, Sarkadi B: Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem 1993;268:21493-21496.
20. Holló Z, Homolya L, Davis CW, Sarkadi B: Calcein accumulation as a fluorometric functional assay of the multidrug transporter. Biochim Biophys Acta 1994;1191:384-388.
21. Sarkadi B, Homolya L, Hollo Z: Assay and reagent kit for evaluation of multi-drug resistance in cells. Application Ser. No. 840791. Filed April 23, 2001. International PCT Publication Date: May 21, 2002.
22. Yoshimura A, Shudo N, Ikeda SI, Ichikawa M, Sumizawa T, Akiyama SI: Novel screening method for agents that overcome classical multidrug resistance in a human cell line. Cancer Lett 1990;50:45-51.
23. Karászi E, Jakab K, Homolya L, Szakács G, Holló Z, Telek B, et al.: Calcein assay for multidrug resistance reliably predicts therapy response and survival rate in acute myeloid leukaemia. Br J Haematol 2001;112:308-314.
24. www.solvo.hu. (Last accessed on March 2, 2007.)
25. Moldenhauer G, Momburg F, Möller P, Schwartz R, Hämmerling GJ: Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker. Br J Cancer 1987;56:714-721.
26. Momburg F, Moldenhauer G, Hämmerling GJ, Möller P: Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res 1987;47:2883-2891.
27. Yaziji H, Battifora H, Barry TS, Hwang HC, Bacchi CE, McIntosh MW, et al.: Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol 2006;19:514-523.
28. http://www.ebioscience.com/ebioscience/appls/Dyes.htm. (Last accessed on March 2, 2007.)
29. www.clinicaltrials.gov. (Last accessed on March 2, 2007.)
30. EDR - Extreme Drug Resistance. www.onchotech.com. (Last accessed on March 2, 2007.)
31. Wall DM, Sparrow R, Hu XF, Nadalin G, Zalcberg JR, Marschner IC, et al.: Clinical application of a rapid, functional assay for multidrug resistance based on accumulation of the fluorescent dye, fluo-3. Eur J Cancer 1993;29A: 1024-1027.
32. Raviv Y, Pollard HB, Bruggemann EP, Pastan I, Gottesman MM: Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J Biol Chem 1990;265:3975-3980.
33. Kularatne BY, Lorigan P, Browne S, Suvarna SK, Smith MO, Lawry J: Monitoring tumour cells in the peripheral blood of small cell lung cancer patients. Cytometry 2002;50:160-167.
34. Friedman MT, Gentile P, Tarectecan A, Fuchs A: Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions. Arch Pathol Lab Med 1996;120:959-966.
35. Risberg B, Davidson B, Nielsen S, Dong HP, Christensen J, Johansen P, et al.: Detection of monocyte/macrophage cell populations in effusions: a comparative study using flow cytometric immunophenotyping and immunocytochemistry. Diagn Cytopathol 2001;25:214-219.
36. Jiao W, Yakushiji H, Kitajima Y, Ogawa A, Miyazaki K: Establishment and characterization of human hilar bile duct Carcinoma cell line and cell strain. J Hepatobiliary Pancreat Surg 2000;7:417-425.
37. Risberg B, Davidson B, Dong HP, Nesland JM, Berner A: Flow cytometric immunophenotyping of serous effusions and peritoneal washings: comparison with immunocytochemistry and morphological findings. J Clin Pathol 2000;53:513-517.
38. Barrett MT, Glogovac J, Prevo LJ, Reid BJ, Porter P, Rabinovitch PS: High-quality RNA and DNA from flow cytometrically sorted human epithelial cells and tissues. Biotechniques 2002;32:888-890, 892, 894, 896.
39. Li G, Passebosc-Faure K, Lambert C, Gentil-Perret A, Blanc F, Oosterwijk E, et al.: Flow cytometric analysis of antigen expression in malignant and normal renal cells. Anticancer Res 2000;20:2773-2778.
40. Henrich CJ, Bokesch HR, Dean M, Bates SE, Robey RW, Goncharova EI, et al.: A high-throughput cell-based assay for inhibitors of ABCG2 activity. J Biomol Screen 2006;11:176-183.
41. de Jong FA, de Jonge MJ, Verweij J, Mathijssen RH: Role of pharmacogenetics in irinotecan therapy. Cancer Lett 2006;234:90-106.
42. Gutmann H, Hruz P, Zimmermann C, Beglinger C, Drewe J: Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. Biochem Pharmacol 2005;70:695-699.
43. Gupta N, Martin PM, Miyauchi S, Ananth S, Herdman AV, Martindale RG, et al.: Down-regulation of BCRP/ABCG2 in colorectal and cervical cancer. Biochem Biophys Res Commun 2006;343:571-577.